MYCB1 develops ALETTA, a proprietary platform that leverages generative AI and real-world evidence (RWE) to enable personalised, evidence-driven healthcare and lifestyle solutions. The company integrates pharmaceutical manufacturing and pharmacy operations with software engineering to create end-to-end personalised therapies and services. MYCB1 and its subsidiaries (MYCB1 B.V. and MYCB1 GmbH) hold certifications enabling market entry in the Netherlands and Germany and have secured GMP, ISO9001, HKZ, ISO27001 and NEN7510 certifications to support product quality and patient-data protection. The group has established distribution agreements in Scandinavia and is negotiating partnerships across Europe, Asia and Latin America as part of its commercial expansion. Founded in 2017, MYCB1 is preparing to list publicly and has arranged financing that it says will underpin its capital position post-IPO. The company’s current financing arrangement provides flexible access to capital as it executes its public-listing strategy.

Total raised

$33M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2023